Navigating Global Pharma Policy
Navigate the intricate dynamics of tariffs on the global pharmaceutical industry through this insightful content series. With contributions from A&M experts on both sides of the Atlantic, this series explores the economic, operational, and legal challenges posed by international trade policies. From the potential disruption of global supply chains to the strategic responses of leading pharmaceutical companies, A&M's Global Life Sciences team offers a comprehensive analysis of how the industry is navigating this evolving landscape.
Gain valuable perspectives on financial optimization, supply chain resilience, and regulatory compliance, as well as the broader geopolitical implications of these tariffs. Whether you're a stakeholder in the pharmaceutical sector or simply interested in the intersection of trade and healthcare, this series provides actionable insights and thought leadership from professionals deeply embedded in the industry.
What the UK-US pharma deal means for patients, innovation and industry
A New Transatlantic Announcement
The UK and the US have agreed a pharmaceutical trade arrangement that eliminates tariffs on UK exports to the American market, in exchange for a commitment to increase spending on innovative medicines by 2028. This deal forms part of a broader package of UK life sciences reforms, which also includes faster clinical trial approvals and the creation of a new national health data service. Together, these measures are designed to revive stalled investment by reducing pricing and regulatory uncertainty.
With cheaper access to the US and clearer pricing frameworks, the environment for pharmaceutical R&D and manufacturing appears more stable. As a result, pharma companies should reassess the UK as a priority launch hub and consider targeted investment in local manufacturing and supply chain capabilities.
Stay informed as we continue to explore the evolving landscape of U.S. trade policies and their impact on the global pharmaceutical industry. This series will be updated regularly to reflect the latest developments, offering fresh insights and strategies to navigate the challenges ahead. Follow along as we analyze policy shifts, industry responses, and the broader implications for global healthcare and trade.
EXPLORE OTHER PARTS OF THIS SERIES
The Effect of Trump's Tariffs on the European Pharma Industry | |||
| 
| 
| 
|
The Profit Crunch: How US Policy Could Reshape Global Pharma R&D | |||
| 
|
